Financial Statements and Supplementary Information

December 31, 2018 and 2017



Table of Contents December 31, 2018 and 2017

	Page
Independent Auditors' Report	1
Financial Statements	
Balance Sheets	3
Statements of Operations and Changes in Net Assets	4
Statements of Cash Flows	5
Notes to Financial Statements	6
Supplementary Information	
Schedule of Expenditures of Federal Awards	17
Notes to Schedule of Expenditures of Federal Awards	18
Internal Control and Compliance Reports	
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	19
Independent Auditors' Report on Compliance for the Federal Major Program and Report on Internal Control over Compliance Required by the Uniform Guidance	21
Schedule of Findings and Questioned Costs	23



Independent Auditors' Report

To the Board of Directors of Long Island FQHC, Inc.

Report on the Financial Statements

We have audited the accompanying financial statements of Long Island FQHC, Inc. ("LIFQHC"), which comprise the balance sheets as of December 31, 2018 and 2017, and the related statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Long Island FQHC, Inc. as of December 31, 2018 and 2017, the results of its operations, changes in net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Report on Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards, as required by Title 2 U.S. Code of Federal Regulations (CFR) Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain other procedures, including comparing and reconciling such information directly to the underlying accounting and other additional statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated May 22, 2019 on our consideration of LIFQHC's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering LIFQHC's internal control over financial reporting and compliance.

Baker Tilly Virchaw Krause, LLP

New York, New York May 22, 2019

Long Island FQHC, Inc. Balance Sheets

Balance Sheets December 31, 2018 and 2017

		2018	 2017
Assets			
Current Assets Cash and cash equivalents Patient services receivable, net (Note 3) Grant receivables Delivery System Reform Incentive Payment (DSRIP) receivable Patient Activation Measure Survey (PAM) contract receivable NYS meaningful use receivable Care Management receivable Value based contract receivable Other receivable Prepaid expenses and other current assets	\$	8,920,843 5,418,525 1,064,712 1,250,684 322,369 379,950 312,390 312,350 774,803 463,338	\$ 9,754,408 3,522,873 1,953,445 1,703,500 276,373 806,617 287,709 1,042,109 90,414 578,538
Total current assets		19,219,964	20,015,986
Property and Equipment, Net (Note 4)		10,154,379	9,947,233
Security and Escrow Deposits		96,294	 69,746
Total assets	\$	29,470,637	\$ 30,032,965
Liabilities and Net Assets			
Current Liabilities Current portion of long-term debt (Note 5) Accounts payable and accrued expenses Accrued compensation Refundable advances Due to Co-Applicant and other party (Note 7 and Note 9)	\$	262,997 2,049,922 799,068 1,799,832 1,892,829	\$ 251,736 2,236,846 578,419 - 4,513,789
Total current liabilities		6,804,648	7,580,790
Long-Term Debt, Net of Current Portion (Note 5)		2,323,413	 2,586,411
Total liabilities		9,128,061	10,167,201
Net Assets Net assets without donor restrictions Total liabilities and net assets		20,342,576	 19,865,764
	þ	29,470,637	\$ 30,032,905

Long Island FQHC, Inc. Statements of Operations and Changes in Net Assets Years Ended December 31, 2018 and 2017

	2018	2017
Revenues without donor restrictions		
Net patient service revenues	\$ 21,567,898	\$ 22,623,157
Provision for bad debts	(425,959)	(511,260)
Net patient service revenues less provision for bad debts	21,141,939	22,111,897
Managed care medical home and bonuses	2,518,713	2,283,872
NYS meaningful use	(129,167)	401,250
Grant revenue:	5 000 000	0 500 000
Article VI	5,000,000	2,500,000
WIC grant revenue Residency grant revenue	1,604,533 2,806,972	1,537,983 3,083,009
Sub-recipient grant revenue	1,053,296	1,099,955
Other grant revenue	430,590	208,930
Other revenue:	400,000	200,000
Delivery System Reform Incentive Payment (DSRIP) Revenue	1,160,139	1,808,557
Care management revenue	2,032,294	1,671,582
Patient Activation Measure Survey (PAM) contract revenue	677,168	301,331
Other revenue	564,945	678,888
Total revenues	38,861,422	37,687,254
-		i
Expenses	16 080 500	14 405 500
Salaries and wages	16,280,529	14,495,596
Fringe benefits	4,068,150	3,329,090
Contract labor, providers Professional services	8,560,321	9,543,034
	2,368,405	2,700,083
Supplies	2,275,787	1,803,274
Laboratory, radiology Travel, conference and meeting	890,241 280,678	946,387 245,775
Space costs	2,074,875	1,928,581
Equipment repairs/maintenance	149,103	128,938
Insurance	159,656	115,542
Telecommunications	369,885	735,277
Dues, licensing and subscription	477,069	443,708
Printing, publication and postage	119,967	100,911
Recruitment and public information	91,190	150,934
Interest	119.459	123.554
Other	123,706	146,510
Total expenses	38,409,021	36,937,194
Total operating income before depreciation	452,401	750,060
Depreciation	788,576	651,773
Revenues (less than) in excess of expenses	(336,175)	98,287
Capital Restructuring Finance Program (CRFP)	487,942	2,500,000
Delivery System Report Incentive Payment (DSRIP) Dental Expanded Capacity Grant	325,045	33,835
Increase in net assets without donor restrictions	476,812	2,632,122
Net Assets Without Donor Restrictions, Beginning	19,865,764	17,233,642
Net Assets Without Donor Restrictions, Ending	\$ 20,342,576	\$ 19,865,764

See notes to financial statements

Statements of Cash Flows

Years Ended December 31, 2018 and 2017

Cash Flows from Operating ActivitiesIncrease in net assets without donor restrictions to net cash (used in) provided by operating activities: Provision for bad debts\$ 476,812\$ 2,632,122Adjustments to reconcile increase in net assets without donor restrictions to net cash (used in) provided by operating activities: Provision for bad debts422,959\$11,260Depreciation788,576661,773Capital grants(812,987)(2,533,835)Changes in assets and liabilities: Patient services receivable(2,321,611)2,062,966Other receivables(843,989)(36,766)Delivery System Reform Incentive Payment (DSRIP) receivable485,733(841,561)Patient colvables(843,993)(276,373)NYS meaningful use receivable(24,667(154,750)Care management receivable(24,667(154,750)Care management receivable(26,548)(60,746)Due to Co-Applicant and other party(2,62,960)3,026,388Accured compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(295,722)(7,400,831)Proceeds from capital grants(251,737)(161,853)Proceeds from insuance of long-term debtAccured on present on the party(265,725)(5,371,982)(Decrease) increase in cash and cash equivalents(83,565)1,482,693Cash Flows from Investing Activities <td< th=""><th></th><th colspan="2">2018</th><th></th><th colspan="2">2017</th></td<>		2018			2017	
Increase in net assets without donor restrictions to net cash (used in) provided by operating activities: Provision for bad debts\$ 476,812\$ 2,632,122Adjustments to reconcile increase in net assets without donor restrictions to net cash (used in) provided by operating activities: Pratient activations activities: Provision for bad debts425,959511,260Depreciation Capital grants(812,987)(2,533,835)Changes in assets and liabilities: Patient services receivable(2,321,611)2.062,966Other receivables Grant receivables(843,399)(36,768)Delivery System Reform Incentive Payment (DSRIP) receivable(484,839)(34,753)Ratin to exclusible(24,881)430,475Value based contract receivable(24,881)430,475Value based contract receivable(26,548)(69,746)Due ivery and escrow deposits(26,548)(69,746)Due to Co-Applicant and other party Accounts payable and accrued expenses(168,924)444,180Accounts payable and accrued expenses(168,924)448,180Accounts payable and accrued expenses(166,924)(162,981)Repayment of long-term debt(261,737)(161,853)Proceeds from insuance o	Cash Flows from Operating Activities					
To net cash (used in) provided by operating activities:425,959511,260Provision for bad debts425,959511,260Depreciation788,576661,773Capital grants(812,987)(2,533,835)Changes in assets and liabilities:(2,321,611)2,062,966Other receivables(2,321,611)2,062,966Other receivables(844,389)(36,768)Delivery System Reform Incentive Payment (DSRIP) receivable452,816(1,248,253)Grant receivables(844,389)(36,768)Delivery System Reform Incentive Payment (DSRIP) receivable(45,996)(276,373)NYS meaningful use receivable(24,681)430,475Care management receivable(24,681)430,475Value based contract receivable(26,548)(66,744)Due to Co-Applicant and other current assets115,200134,754Security and escrow deposits(26,548)(66,744)Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(166,924)(182,981)Refundable advances1,799,832Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Financing Activities(995,722)(7,400,831)Proceeds from issuance of long-term debt-3,000,000Net cash used in investing activities(633,655)1,482,693Cash Flows from Financing Activities(633,655)1,482,693Proceeds from asitial grants(51,250)5,371,982 <td></td> <td>\$</td> <td>476,812</td> <td>\$</td> <td>2,632,122</td>		\$	476,812	\$	2,632,122	
Provision for bad debts425,959511,260Depreciation788,576661,773Capital grants(812,987)(2,533,835)Changes in assets and liabilities:(812,987)(2,533,835)Patient services receivable(2,321,611)2,062,966Other receivables(884,389)(36,768)Delivery System Reform Incentive Payment (DSRIP) receivable(884,389)(36,768)Grant receivables(884,373)(841,561)Patient Activation Measure Survey (PAM) contract receivable(46,996)(276,373)NYS meaningful use receivable(24,681)430,475Value based contract receivable(24,681)430,475Value based contract receivable(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accrued compensation220,649(182,981)Refundable advances(17,99,832)-Net cash (used in) provided by operating activities(295,722)(7,400,831)Proceeds from Financing Activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,		·	- , -	,	,,	
Provision for bad debts425,959511,260Depreciation788,576661,773Capital grants(812,987)(2,533,835)Changes in assets and liabilities:(812,987)(2,533,835)Patient services receivable(2,321,611)2,062,966Other receivables(884,389)(36,768)Delivery System Reform Incentive Payment (DSRIP) receivable(884,389)(36,768)Grant receivables(884,373)(841,561)Patient Activation Measure Survey (PAM) contract receivable(46,996)(276,373)NYS meaningful use receivable(24,681)430,475Value based contract receivable(24,681)430,475Value based contract receivable(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accrued compensation220,649(182,981)Refundable advances(17,99,832)-Net cash (used in) provided by operating activities(295,722)(7,400,831)Proceeds from Financing Activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,	,					
Depreciation788,576651,773Capital grants(812,987)(2,533,835)Changes in assets and liabilities:(2,321,611)2,062,966Other receivables(843,389)(36,768)Delivery System Reform Incentive Payment (DSRIP) receivable452,816(1,242,253)Grant receivables888,733(841,561)Patient Activation Measure Survey (PAM) contract receivable426,667(154,750)Care management receivable(24,681)430,475Value based contract receivable729,759(1,042,109)Prepaid expenses and other current assets115,200134,754Security and escrow deposits(26,548)(69,746)Due to Co-Applicant and other party(2,620,60)3,026,388Accounts payable and accrued expenses(186,824)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Ending§ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$ 9,754,408 <td></td> <td></td> <td>425,959</td> <td></td> <td>511,260</td>			425,959		511,260	
Capital grants (812,987) (2,533,835) Changes in assets and liabilities: (2,221,611) 2,062,966 Other receivables (843,389) (36,768) Delivery System Reform Incentive Payment (DSRIP) receivable 452,216 (1,242,233) Grant receivables 888,733 (841,561) Patient Activation Measure Survey (PAM) contract receivable 426,667 (154,750) Care management receivable (24,681) 430,475 Value based contract receivable (24,681) 430,475 Value based contract receivable (24,681) (10,42,109) Prepaid expenses and other current assets 115,200 134,754 Security and escrow deposits (2,624) (69,746) Due to Co-Applicant and other party (2,620,960) 3,026,388 Accounts payable and accrued expenses (186,924) 448,180 Accured compensation 220,649 (182,981) Refundable advances 1,799,832 - Purchases of property and equipment (995,722) (7,400,831) Net cash used in investing activitites (995,722) (7	Depreciation				-	
Changes in assets and liabilities:Patient services receivable(2,321,611)2,062,966Other receivables(684,389)(36,768)Delivery System Reform Incentive Payment (DSRIP) receivable452,816(1,242,253)Grant receivables888,733(841,561)Patient Activation Measure Survey (PAM) contract receivable(45,996)(276,373)NYS meaningful use receivable(24,681)430,475Value based contract receivable(24,681)430,475Value based contract receivable729,759(1,042,109)Prepaid expenses and other current assets(15,200)134,754Security and escrow deposits(26,648)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(166,524)448,180Accourd compensation220,644(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing ActivitiesPurchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(251,737)(161,853)Proceeds from capital grants812,9872,533,855Proceeds from capital grants561,2505,371,982Other end bet-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, B					-	
Patient services receivable (2,321,611) 2,062,966 Other receivables (684,389) (687,88) Delivery System Reform Incentive Payment (DSRIP) receivable 452,2816 (1,244,253) Grant receivables 888,733 (841,561) Patient Activation Measure Survey (PAM) contract receivable 445,986) (276,373) NYS meaningful use receivable (24,681) 430,475 Value based contract receivable (24,681) 430,475 Value based contract receivable (24,681) 430,475 Value based contract receivable (26,548) (69,746) Due to Co-Applicant and other party (2,620,960) 3,026,388 Accounts payable and accrued expenses (186,924) 448,180 Accounds payable and accrued expenses (186,924) 448,180 Accounds payable and accrued expenses (1995,722) (7,400,831) Refundable advances 1.799,832 - Net cash (used in investing activities (995,722) (7,400,831) Net cash used in investing activities (995,722) (7,400,831) Proceeds from capital grants			(-))		())	
Other receivables(684,389)(36,768)Delivery System Reform Incentive Payment (DSRIP) receivable452,816(1,248,253)Grant receivables888,733(841,561)Patient Activation Measure Survey (PAM) contract receivable(45,996)(276,373)NYS meaningful use receivable(24,681)430,475Value based contract receivable(24,681)430,475Value based contract receivable(24,681)430,475Value based contract receivable(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(251,737)(161,853)Proceeds from capital grants(251,737)(161,853)Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities(251,250)5,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending§ 8,920,843§ 9,754,408Supplemental Disclosure of Cash Flow Information11	5		(2.321.611)		2.062.966	
Delivery System Reform Incentive Payment (DSRIP) receivable452,816(1,248,253)Grant receivables888,733(841,561)Patilent Activation Measure Survey (PAM) contract receivable(45,996)(276,373)NYS meaningful use receivable426,667(154,750)Care management receivable(24,881)430,475Value based contract receivable(24,881)430,475Value based contract receivable(26,548)(69,746)Due to Co-Applicant and other party(26,548)(69,746)Due to Co-Applicant and other party(26,20,960)3,026,388Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Net cash used in investing activities(251,737)(161,853)Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending§ 8,920,8439,754,408Supplemental Disclosure of Cash Flow InformationSupplemental Disclosure of Cash Flow Information						
Grant receivables888,733(841,561)Patient Activation Measure Survey (PAM) contract receivable(45,996)(276,373)NYS meaningful use receivable(24,681)430,475Value based contract receivable(24,681)430,475Value based contract receivable(24,681)(430,475Value based contract receivable(26,548)(69,746)Due to Co-Applicant and other party(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3.026,388Accounts payable and accrued expenses(186,924)448,180Accound compensation220,649(182,981)Refundable advances1,799,832Net cash (used in) provided by operating activities(399,093)3.511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending§ 8,920,843§ 9,754,408Supplemental Disclosure of Cash Flow Information\$8,920,843\$ 9,754,408						
Patient Activation Measure Survey (PAM) contract receivable(45,996)(276,373)NYS meaningful use receivable426,667(154,750)Care management receivable(24,681)430,475Value based contract receivable729,759(1,042,109)Prepaid expenses and other current assets115,200134,754Security and escrow deposits(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(251,737)(161,853)Proceeds from Einancing Activities(251,737)(161,853)Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,665)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$ 8,920,843\$ 9,754,408					()	
NYS meaningful use receivable426.667(154,750)Care management receivable(24,681)430,475Value based contract receivable729,759(1,042,109)Prepaid expenses and other current assets115,200134,754Security and escrow deposits(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Cash Flows from Financing Activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending§ 8,920,843§ 9,754,408Supplemental Disclosure of Cash Flow Information\$8,970,843			,		· · · · ·	
Care management receivable(24,681)430,475Value based contract receivable729,759(1,042,109)Prepaid expenses and other current assets115,200134,754Security and escrow deposits(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Proceeds from Financing Activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$8,920,843\$ 9,754,408	• • •		()		· · · · ·	
Value based contract receivable729,759(1,042,109)Prepaid expenses and other current assets115,200134,754Security and escrow deposits(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,348Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Net cash used in investing activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Ending9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$ 8,920,843\$ 9,754,408	5				· · · · ·	
Prepaid expenses and other current assets115,200134,754Security and escrow deposits(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Net cash used in investing activities(251,737)(161,853)Proceeds from Financing Activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$\$			()		-	
Security and escrow deposits(26,548)(69,746)Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$8,920,843\$ 9,754,408			,		· · · · ·	
Due to Co-Applicant and other party(2,620,960)3,026,388Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing ActivitiesPurchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(995,722)(7,400,831)Repayment of long-term debt(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending§ 8,920,843§ 9,754,408Supplemental Disclosure of Cash Flow InformationSupplemental Disclosure of Cash Flow Information					,	
Accounts payable and accrued expenses(186,924)448,180Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from capital grants561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$ 8,920,843\$ 9,754,408			. ,		. ,	
Accrued compensation220,649(182,981)Refundable advances1,799,832-Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(995,722)(7,400,831)Repayment of long-term debt(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$\$ 9,754,408			· · · /			
Refundable advances1,799,832Net cash (used in) provided by operating activities(399,093)Cash Flows from Investing Activities(995,722)Purchases of property and equipment(995,722)Net cash used in investing activities(995,722)Cash Flows from Financing Activities(995,722)Repayment of long-term debt(251,737)Proceeds from capital grants812,987Proceeds from issuance of long-term debt-Net cash provided by financing activities561,250(Decrease) increase in cash and cash equivalents(833,565)Integes (Cash and Cash Equivalents, Ending9,754,408Supplemental Disclosure of Cash Flow Information\$ 8,920,843			(,		-	
Net cash (used in) provided by operating activities(399,093)3,511,542Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$8,920,843\$ 9,754,408	•				(182,981)	
Cash Flows from Investing Activities(995,722)(7,400,831)Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(995,722)(7,400,831)Repayment of long-term debt(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information561,2505,371,982	Refundable advances		1,799,832		-	
Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(251,737)(161,853)Repayment of long-term debt(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information55	Net cash (used in) provided by operating activities		(399,093)		3,511,542	
Purchases of property and equipment(995,722)(7,400,831)Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(251,737)(161,853)Repayment of long-term debt(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information55	Cash Flows from Investing Activities					
Net cash used in investing activities(995,722)(7,400,831)Cash Flows from Financing Activities(251,737)(161,853)Repayment of long-term debt(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information\$8,920,843\$ 9,754,408	5		(995,722)		(7,400,831)	
Cash Flows from Financing ActivitiesRepayment of long-term debt(251,737)Proceeds from capital grants812,987Proceeds from issuance of long-term debt-Net cash provided by financing activities561,250(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,408\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information	· · · · · · · · · · · · · · · · · · ·				() / - /	
Repayment of long-term debt(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information	Net cash used in investing activities		(995,722)		(7,400,831)	
Repayment of long-term debt(251,737)(161,853)Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information	Cash Flows from Financing Activities					
Proceeds from capital grants812,9872,533,835Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information55	-		(251,737)		(161,853)	
Proceeds from issuance of long-term debt-3,000,000Net cash provided by financing activities561,2505,371,982(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information55			812,987		2,533,835	
(Decrease) increase in cash and cash equivalents(833,565)1,482,693Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow InformationSupplemental Disclosure of Cash Flow InformationSupplemental Disclosure of Cash Flow Information					3,000,000	
Cash and Cash Equivalents, Beginning9,754,4088,271,715Cash and Cash Equivalents, Ending\$ 8,920,843\$ 9,754,408Supplemental Disclosure of Cash Flow Information	Net cash provided by financing activities		561,250		5,371,982	
Cash and Cash Equivalents, Ending \$ 8,920,843 \$ 9,754,408 Supplemental Disclosure of Cash Flow Information	(Decrease) increase in cash and cash equivalents		(833,565)		1,482,693	
Supplemental Disclosure of Cash Flow Information	Cash and Cash Equivalents, Beginning		9,754,408		8,271,715	
	Cash and Cash Equivalents, Ending	\$	8,920,843	\$	9,754,408	
	Supplemental Disclosure of Cash Flow Information					
		\$	119,459	\$	123,564	

Notes to Financial Statements Years Ended December 31, 2018 and 2017

1. Organization

Long Island FQHC, Inc. ("LIFQHC") is an independent not-for-profit corporation formed on May 14, 2009 and established by the New York State Department of Health ("NYSDOH") on June 15, 2010, as a co-operator of four community health centers and a school-based clinic, previously operated solely by the Nassau Health Care Corporation ("NHCC"), in order to meet federal governance requirements and obtain designation from the Health Resources and Services Administration ("HRSA") as a public entity federally qualified health center ("FQHC") "Look Alike" organization. LIFQHC is licensed under Article 28 of the New York State public health law.

As of December 31, 2018, LIFQHC is the co-operator of seven in-scope community health centers in Nassau County.

NHCC is a public benefit corporation created for the purposes of acquiring the health facilities owned by Nassau County, New York ("County"), operating these facilities more efficiently than the County could, and competing with other health care providers in a rapidly changing health care marketplace.

HRSA recognizes two governance models through which the operations of a FQHC can be overseen: the *voluntary model* and the *public-entity model*. In the voluntary model, HRSA requires the governing entity to be a not-for-profit corporation with at least 51 percent of the directors on the board obtaining health care services from the FQHC. In the public entity model, HRSA permits health centers to be co-operated by a public entity, such as a public benefit corporation, in conjunction with an independent not-for-profit FQHC entity, again with at least 51 percent of the directors of the not-for-profit board obtaining care from the FQHC. In the public entity's board and the not-for-profit's FQHC operate under a Co-Applicant Agreement. The Co-Applicant Agreement delineates the rights and responsibilities of each governing board, consistent with the minimum governance requirements set forth by HRSA.

NHCC and LIFQHC executed a Co-Applicant Agreement. LIFQHC, through the Co-Applicant Agreement, was empowered to adopt health center policies, including those on the scope and availability of services, location and hours of services, and quality control; approve the annual budget; approve the selection and dismissal of the Executive Director of the FQHC; approve the application for subsequent grants and FQHC recertification; evaluate FQHC activities; and implement a compliance program.

NHCC retained the right to establish personnel policies and procedures to NHCC employees only; provide staff to the current health centers; develop financial and operational management systems, and guide the long range strategic planning process. HRSA granted Look Alike status under the public entity model, and LIFQHC became operational in June 2010. In July of 2011, Long Island FQHC, Inc. received grantee status with HRSA as a sub-recipient of Hudson River Healthcare.

2. Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Notes to Financial Statements Years Ended December 31, 2018 and 2017

Cash and Cash Equivalents

Cash and cash equivalents include money market funds. LIFQHC maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed federally insured limits. LIFQHC has not experienced any losses in such accounts.

Patient Services Receivable, Net

Patient services receivable result from the health care services provided by LIFQHC. Additions to the allowance for doubtful accounts result from the provision for bad debts. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts. The amount of the allowance for doubtful accounts is based upon management's assessment of historical and expected net collections, business and economic conditions, trends in Medicare and Medicaid health care coverage and other collection indicators.

For receivables associated with services provided to patients who have third-party coverage, which includes patients with deductible and copayment balances due for which third-party coverage exists for part of the bill, LIFQHC analyzes contractually due amounts and provides an allowance for doubtful accounts and a provision for bad debts, if necessary. For receivables associated with self-pay patients, LIFQHC records a significant provision for bad debts in the period of service on the basis of its past experience, which indicates that many patients are unable to pay the portion of their bill for which they are financially responsible. The difference between the billed rates and the amounts actually collected after all reasonable collection efforts have been exhausted is charged off against the allowance for doubtful accounts. LIFQHC had not changed their financial assistance policy in 2018. LIFQHC does not maintain a material allowance for doubtful accounts from third-party payors, nor did it have significant write-offs from third-party payors.

Patient services receivable, net of allowance for doubtful accounts and contractual allowances and discounts, consists of the following:

			2018		
	R	Gross eceivables	ntractual and Charitable Allowances	S	et Patient Services eceivable
Medicaid Medicaid managed care Medicare Private insurance Self-pay	\$	2,411,573 18,848,545 6,032,296 5,579,377 9,873,929	\$ 1,625,082 18,159,559 5,632,111 4,631,251 9,873,276	\$	786,491 688,986 400,185 948,126 653
	\$	42,745,720	\$ 39,921,279		2,824,441
NYS Medicaid Wrap, net Safety net payments					1,035,425 1,558,659
Total				\$	5,418,525

Notes to Financial Statements Years Ended December 31, 2018 and 2017

				2017	
	R	Gross eceivables	(ntractual and Charitable Illowances	et Patient Services eceivable
Medicaid Medicaid managed care Medicare Private insurance Self-pay	\$	2,099,150 8,457,234 1,062,852 1,642,830 1,992,824	\$	1,120,689 8,377,307 933,460 1,180,044 1,992,172	\$ 978,461 79,927 129,392 462,786 652
NYS Medicaid Wrap, net	\$	15,254,890	\$	13,603,672	1,651,218
Safety net payments Total					\$ 678,111 3,522,873

Net Patient Service Revenues

Net patient service revenues is reported at the estimated net realizable amounts from patients, thirdparty payors and others for services rendered. Self-pay revenue is recorded at published charges with charitable allowances deducted to arrive at net self-pay revenue. All other patient service revenues are recorded at published charges with contractual allowances deducted to arrive at patient services, net. Reimbursement rates are subject to revisions under the provisions of reimbursement regulations. Adjustments for such revisions are recognized in the fiscal year incurred.

Charity Care

LIFQHC maintains records to identify and monitor the level of charity care that it provides. The costs associated with the charitable care services provided are estimated by applying the cost-to-charge ratio from the most recently filed cost report, to the amount of gross uncompensated charges for the patients receiving charity care net of the Safety Net Payment. Total such costs were \$3,006,249 and \$1,721,505 for the years ended December 31, 2018 and 2017, respectively.

Other Receivables

Other revenue consist of quality incentives and care management payment when earned.

Property and Equipment, Net

Property and equipment acquisitions are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets ranging from 3 to 39 years using a half month convention. Maintenance, repairs and minor renewals are expensed as incurred. Assets are written off when disposed of or fully depreciated as determined by management. Leasehold improvements are amortized on a straight-line basis over the estimated useful life of the improvement or the term of the lease, whichever is less.

Property and equipment are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. If long-lived assets are deemed impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds fair value. No impairments were recorded in 2018 and 2017.

Notes to Financial Statements Years Ended December 31, 2018 and 2017

Grant Revenue

Revenue from government grants and contracts designated for use in specific activities is recognized in the period when expenditures have been incurred in compliance with the grantor's restrictions. Grants and contracts awarded for the acquisition of long-lived assets are reported as net assets without donor restriction, in the absence of donor stipulations to the contrary, when placed in service. Cash received in excess of revenue recognized is recorded as refundable advances. Grant and contract receivables are reported at their outstanding unpaid balances. LIFQHC writes off accounts receivable against the allowance when a balance is determined to be uncollectible.

Under an executed agreement between the NHCC and the County, LIFQHC received \$5,000,000 in 2018 and \$2,500,000 in 2017 in Article VI health center grants. The agreement was originally in effect until December 31, 2014. On December 19, 2016, the agreement was extended to December 31, 2020. The Article VI health center grants are given to LIFQHC as part of the agreement to provide medical services such as HIV screening and tuberculosis testing.

LIFQHC receives funding under the Capital Restructuring Financing Program ("CRFP") from the New York State Department of Health. The contract period under the CRFP is April 1, 2015 through March 31, 2020. LIFQHC received \$2,500,000 during 2017 under the CRFP and used part of the funding in addition to issuing new debt (see Note 5) to purchase two existing properties for \$5,905,000 and certain renovations during 2017 (see Note 4).

Refundable Advances

Refundable advances represent amounts received subject to certain conditions. Refundable advances will be recognized as revenue when conditions are satisfied.

Revenues (Less Than) in Excess of Expenses

The statements of operations and changes in net assets includes the determination of revenues (less than) in excess of expenses. LIFQHC considers all of its health care and related activities to be part of normal operations and considers the caption revenues (less than) in excess of expenses to be its performance indicator.

Changes in net assets without donor restrictions, which are excluded from revenues (less than) in excess of expenses, consistent with industry practice, includes contributions of long-lived assets (including assets acquired using contributions, which by donor restriction were used for the purpose of acquiring such assets) and capital contributions.

Income Taxes

LIFQHC is a not-for-profit corporation as described in Section 501(c)(3) of the Internal Revenue Code and is exempt from federal income taxes on its exempt income under Section 501(a) of the Internal Revenue Code. LIFQHC accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the tax uncertainty occurs if the recognition threshold has been met. Management determined that there were no tax uncertainties that met the recognition threshold in 2018 and 2017. LIFQHC does not perform any activities that would be subject to unrelated business income tax; therefore, it has not filed Form 990-T, *Exempt Organization Business Income Tax Return*.

Reclassifications

Certain reclassifications have been made to the 2017 amounts to conform to the current year presentations.

Notes to Financial Statements Years Ended December 31, 2018 and 2017

New Accounting Pronouncements

Revenue from Contracts with Customers

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*. ASU No. 2014-09 supersedes the revenue recognition requirements in *Topic 605, Revenue Recognition*, and most industry-specific guidance. Under the requirements of ASU No. 2014-09, the core principle is that entities should recognize revenue to depict the transfer of promised goods or services to customers (patients) in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. LIFQHC will be required to retrospectively adopt the guidance in ASU No. 2014-09 for years beginning after December 15, 2018. The LIFQHC has not yet determined the impact of adoption of ASU No. 2014-09 on its financial statements.

Leases

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)*. ASU No. 2016-02 was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the provisions of ASU No. 2016-02, a lessee is required to recognize a right-to-use asset and lease liability, initially measured at the present value of the lease payments, in the balance sheet. In addition, lessees are required to provide qualitative and quantitative disclosures that enable users to understand more about, the nature of the lessee's leasing activities. LIFQHC will be required to retrospectively adopt the guidance in ASU No. 2016-02 for years beginning after December 15, 2019. LIFQHC has not yet determined the impact of adoption of ASU No. 2016-02 on its financial statements.

Financial Statements

In 2018, the LIFQHC adopted FASB's ASU No. 2016-14, *Not-for-Profit Entities (Topic 958): Presentation of Financial Statements of Not-for-Profit Entities*. The LIFQHC adopted ASU No. 2016-14, and has applied the changes retrospectively to all periods presented, except for the disclosures around liquidity and availability of resources. This disclosure has been presented for 2018 only, as allowed by ASU No. 2016-14. The new standard changes the following aspects of the financial statements:

- The unrestricted net asset class has been renamed Net Assets Without Donor Restrictions;
- The financial statements include a disclosure about liquidity and availability of resources (Note 12).
- The functional expense disclosure for 2018 and 2017 includes expenses reported by both nature and function (Note 10).

Contributions

In June 2018, the FASB issued ASU 2018-08, Not-for-Profit Entities (Topic 958): *Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made*. The new guidance is intended to clarify and improve accounting guidance for contributions received and contributions made. The amendments in this ASU should assist entities in (1) evaluating whether transactions should be accounted for as contributions (nonreciprocal transactions) or as exchange (reciprocal) transactions subject to other guidance and (2) determining whether a contribution is conditional. ASU 2018-08 is effective for the LIFQHC for the fiscal years beginning after December 15, 2018. Management is currently evaluating the impact that ASU 2018-08 on LIFQHC's financial statements.

Notes to Financial Statements Years Ended December 31, 2018 and 2017

3. Net Patient Service Revenues

LIFQHC recognizes patient service revenues associated with services provided to patients who have Medicaid, Medicare, Third Party Payor and Managed Care plans coverage on the basis of contractual rates for services rendered. For uninsured self-pay patients that do not qualify for charity care, LIFQHC recognizes revenue on the basis of its standard rates for services provided or on the basis of discounted rates if negotiated or provided by LIFQHC's policy. Charity care services are computed using a sliding fee scale based on patient income and family size. On the basis of historical experience, a significant portion of LIFQHC's uninsured patients will be unable or unwilling to pay for the services provided. Thus, LIFQHC records a provision for bad debts related to uninsured patients in the period the services are provided.

Patient service revenues, net of provision for bad debts (charitable allowances) and contractual allowances and discounts, consists of the following:

				2018	
	Gro	oss Charges	(ntractual and Charitable Illowances	Net Patient Service Revenues
Medicaid Medicaid managed care Medicare Private insurance Self-pay	\$	1,178,745 15,405,878 6,401,964 4,425,358 9,085,418	\$	131,763 9,537,583 4,677,747 3,250,889 8,236,075	\$ 1,046,982 5,868,295 1,724,217 1,174,469 849,343
	\$	36,497,363	\$	25,834,057	10,663,306
Safety net payment NYS Medicaid Wrap					 2,236,770 8,241,863
Total					\$ 21,141,939
				2017	
Medicaid Medicaid managed care Medicare Private insurance Self-pay	\$	1,893,879 14,235,103 3,532,811 1,881,243 7,498,922	\$	371,320 8,199,563 1,852,971 608,085 6,731,585	\$ 1,522,559 6,035,540 1,679,840 1,273,158 767,337
	\$	29,041,958	\$	17,763,524	11,278,434
Safety net payment NYS Medicaid Wrap					 3,432,359 7,401,104
Total					\$ 22,111,897

Notes to Financial Statements Years Ended December 31, 2018 and 2017

4. Property and Equipment, Net

Property and equipment, net, at cost, consists of the following:

	2018		 2017	
Land Leasehold improvements Buildings Furniture and fixtures Movable equipment Fixed equipment Computer equipment Software	\$	885,750 3,865,714 5,019,250 354,142 598,069 270,800 662,811 61,518	\$ 885,750 3,348,898 5,019,250 347,940 524,796 267,700 580,995	
		11,718,054	10,975,329	
Less accumulated depreciation Plus construction in progress		(1,888,720) 325,045	 (1,100,144) 72,048	
Total	\$	10,154,379	\$ 9,947,233	

Total interest costs incurred in 2018 were \$119,459.

5. Long-Term Debt

In connection with the purchases of the Elmont property, LIFQHC entered into a \$1,500,000 mortgage from a financial institution during 2017. The mortgage carries a 4.25 percent interest per annum and is for a 10 year term. In addition there is a line of credit with the financial institution for an additional \$1,500,000. An amount of \$1,425,485 was withdrawn during 2017 on the line of credit, which was subsequently paid off during 2017 when the CRFP funds were received. There are no amounts outstanding on the line of credit as of December 31, 2018. The line of credit has a variable interest rate equal to one-half percent per annum above the financial institution's prime rate. The line of credit is being subsequently renewed (see footnote 14).

Also during 2017 LIFQHC in connection with the purchase of the Freeport property, LIFQHC obtained a \$1,500,000 mortgage from a bank for a period of ten years at a rate of 4.40 percent per annum.

Long-term debts are as follows at December 31:

	 2018	 2017
Mortgage (Elmont) Mortgage (Freeport)	\$ 1,270,789 1,315,621	\$ 1,397,935 1,440,212
Less current maturities	 2,586,410 262,997	 2,838,147 251,736
Total	\$ 2,323,413	\$ 2,586,411

Notes to Financial Statements

Years Ended December 31, 2018 and 2017

Scheduled principal repayments per agreement on long-term debt are as follows:

Years ending December 31:	
2019	\$ 262,997
2020	274,480
2021	287,042
2022	299,883
2023	313,299
Thereafter	 1,148,709
Total	\$ 2,586,410

The mortgages are secured by the fixed assets of LIFQHC. LIFQHC is required to meet certain covenants in accordance with the debt agreements.

6. Medical Malpractice Claims Coverage

Under the Services Agreement between NHCC and LIFQHC, NHCC provides professional liability insurance covering the medical services provided by staff to patients of LIFQHC. The insurance requirement is limited to claims arising from services rendered during the term of the Services Agreement, whether the claims arise while the Services Agreement is in effect or after it expires or is terminated by either Party. The professional liability insurance coverage provided by NHCC to LIFQHC is in the minimum amount of \$1,000,000 per occurrence and \$3,000,000 in the aggregate.

LIFQHC maintains its medical malpractice coverage under the Federal Tort Claims Act ("FTCA") for services provided by employees. FTCA provides malpractice coverage to eligible PHS-supported programs and applies to the LIFQHC and its employees while providing services within the scope of employment included under grant-related activities. The Attorney General, through the U.S. Department of Justice, has the responsibility for the defense of the individual and/or grantee for malpractice case approved by FTCA coverage. LIFQHC obtains gap insurance for providers who work at non-scope locations.

7. Other Third Party Transactions

An agreement with NHCC provides for fees to be paid by LIFQHC to NHCC in exchange for staffing, ancillary and administrative services in connection with operating the health centers. The annual fee for these services is NHCC's cost. The due to/from third party in the balance sheet has no payment terms and is non-interest bearing. The expenses incurred for staffing were \$8,658,319 and \$9,644,934 for the years ended December 31, 2018 and 2017, respectively. The expenses incurred for ancillary and administrative services (including contract services disclosed in Note 9) were \$4,045,349 and \$3,837,265 for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018 and 2017, LIFQHC owed NHCC \$1,892,829 and \$4,513,789, respectively.

8. Contingencies

The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations is subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time. Government activity continues to increase with respect to investigations and allegations concerning possible violations by healthcare providers of fraud and abuse statutes and regulations, which could result in the imposition of significant fines and penalties as well as significant repayments for patient service previously billed. Management is not aware of any material incidents of noncompliance; however, the possible future financial effects of this matter on LIFQHC, if any, are not presently determinable.

Notes to Financial Statements Years Ended December 31, 2018 and 2017

9. Lease Commitments

At December 31, 2016, LIFQHC has commitments under noncancelable operating leases for real property rental, having initial terms of five years and expiring on various dates. At December 31, 2018, approximate future minimum rental commitments under noncancelable operating leases are as follows:

Years ending December 31:	
2019	\$ 1,486,247
2020	1,491,469
2021	1,423,652
2022	1,457,495
2023	898,864
Thereafter	 542,706
Total	\$ 7,300,433

Rent expense for the years ended December 31, 2018 and 2017 amounted to \$1,359,312 and \$1,409,354, respectively.

In 2015, LIFQHC extended its contract for services agreement initially dated November 1, 2010 with a company. The extension of the agreement is effective February 1, 2015 and expiring on December 31, 2019. Contracted services expense for the years ended December 31, 2018 and 2017 amounted to \$641,619 and \$1,366,038, respectively.

10. Functional Expenses

Functional expenses have been recorded and reported based on their nature and functionality of expenditures as they are incurred. The methodology allocation is reviewed by Management periodically.

LIFQHC provides health care services to individuals within its geographic location. Expenses related to providing these services in 2018 and 2017 approximate the following:

		2018	
	Health care services	General and administrative	Total
Salaries and wages Fringe benefits Contract labor, providers Professional services Supplies Laboratory, radiology Travel, conference, meeting Space costs Equipment repairs/maintenance Insurance Telecommunications Dues and subscriptions Printing, publication and postage Recruitment and public information Depreciation Interest Other	 \$ 12,639,891 3,620,859 8,560,321 2,260,714 2,275,787 890,241 280,678 2,074,875 149,103 159,656 369,885 477,069 119,967 91,190 788,576 119,459 123,706 	\$ 3,640,638 447,291 - 112,339 - - - - - - - - - - - - - - - - - -	 \$ 16,280,529 4,068,150 8,560,321 2,368,405 2,275,787 890,241 280,678 2,074,875 149,103 159,656 369,885 477,069 119,967 91,190 788,576 119,459 123,706
	\$ 35,001,977	\$ 4,200,268	39,197,597

Notes to Financial Statements Years Ended December 31, 2018 and 2017

	2017			
	Health ca services		Total	
Salaries and wages Fringe benefits Contract labor, providers Professional services Supplies Laboratory, radiology Travel, conference, meeting Space costs Equipment repairs/maintenance Insurance Telecommunications Dues and subscriptions	\$ 11,390, 2,826, 9,543, 2,531, 1,803, 946, 245, 1,928, 128, 115, 735, 443, 100,	417 502,673 ,034 - ,955 168,128 ,274 - ,387 - ,775 - ,581 - ,938 - ,542 - ,277 - ,708 -	\$ 14,495,596 3,329,090 9,543,034 2,700,083 1,803,274 946,387 245,775 1,928,581 128,938 115,542 735,277 443,708 100,911	
Recruitment and public information Depreciation Interest Other	150, 651, 123, 146,	.773 - .554 -	150,934 651,773 123,554 146,510	
	\$ 33,813,	,314 \$ 3,775,653	37,588,967	

11. Retirement Plan

LIFQHC has a 401K profit sharing plan covering substantially all of its employees. Contributions to the plan are based on percentage of salaries. Pension expense amounted to \$602,590 and \$541,034 for the years ended December 31, 2018 and 2017, respectively. Pension expense has been included in fringe benefits expense.

12. Measure of Operations and Liquidity

The following reflects the LIFQHC's financial assets available within one year of the balance sheets date, reduced by amounts not available for general use because of contractual restrictions for general expenditures.

Cash and cash equivalents		8,920,843
Patient services receivable		5,418,525
Financial assets available to meet cash needs for general expenditures within one year		14,339,368

Additionally, LIFQHC has a line of credit of \$1.5 million dollars. There was no outstanding balance at the Balance Sheet Date.

Notes to Financial Statements Years Ended December 31, 2018 and 2017

13. Concentration of Credit Risk

LIFQHC's primary operations and service area include most communities of Nassau County Long Island, New York. LIFQHC grants credit without collateral to its patients, who are insured under third-party payor arrangements, primarily with Medicare, Medicaid, and various commercial insurance companies. The significant concentrations of accounts receivable for services to patients include approximately 64 percent from Medicaid (including Wrap), 11 percent from Medicare, and 25 percent from other third party payors at December 31, 2018 (76 percent from Medicaid (including Wrap), 5 percent from Medicare, and 16 percent from other third party payors at December 31, 2017).

14. Subsequent Events

LIFQHC evaluated subsequent events for recognition or disclosure through May 22, 2019, the date the financial statements were available to be issued. The line of credit is being renewed with the same financial institution under similar terms and is expected to be finalized in June 2019.

Schedule of Expenditures of Federal Awards Year Ended December 31, 2018

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Federal CFDA Number	Pass-Through Agency	Pass-Through Entity Identifying Federal Number Expenditures		
U.S. Department of Health and Human Services: Affordable Care Act, Teaching Health Center					
Graduate Medical Education Payments Program	93.530	Not Applicable	Not Applicable	\$	2,806,972
Health Center Program Cluster: Consolidated Health Centers	93.224	Hudson River Health Care	H80CS00313-13-12		150,000
Pass-Through from New York State Department of Health, Maternal and Child Health Block Grant School Based Health Contract # C32406GG	93.994	Not Applicable	B04MC32560		73,125
Total U.S. Department of Health and Human Services					3,030,097
U.S. Department of Agriculture: Special Supplemental Nutrition Program for Women, Infants, and Children Program	10.557	New York State Department of Health	DOH01-C30434GG-3450000		1,604,533
Total expenditures of federal awards				\$	4,634,630

Notes to Schedule of Expenditures of Federal Awards Year Ended December 31, 2018

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the "Schedule") includes the federal grant activity of the Long Island FQHC, Inc. ("LIFQHC") under programs of the federal government for the year ended December 31, 2018.

The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* ("Uniform Guidance"). Since the Schedule presents only a select portion of the operations of LIFQHC, it is not intended to and does not present the financial position, changes in net assets or cash flows of LIFQHC.

2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown, if any, represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. Pass-through entity identifying numbers are presented when available.

3. Indirect Cost Rate

LIFQHC has elected to use the 10 percent de-minimus indirect cost rate allowed under the Uniform Guidance for the special supplemental Nutrition Program for Women, Infants, and Children Program only. The 10 percent de-minimus indirect cost rate was not available to be selected for any other federal grants.



Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

To the Board of Directors of Long Island FQHC, Inc.

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Long Island FQHC, Inc. ("LIFQHC"), which comprise the balance sheet as of December 31, 2018, and the related statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated May 22, 2019.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered LIFQHC's internal control over financial reporting ("internal control") to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of LIFQHC's internal control. Accordingly, we do not express an opinion on the effectiveness of LIFQHC's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether LIFQHC's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Baker Tilly Virchaw Krause, UP

New York, New York May 22, 2019



Independent Auditors' Report on Compliance for the Federal Major Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

To the Board of Directors of Long Island FQHC, Inc.

Report on Compliance for the Major Federal Program

We have audited Long Island FQHC, Inc.'s ("LIFQHC") compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on LIFQHC's major federal program for the year ended December 31, 2018. LIFQHC's major federal program is identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for LIFQHC's major federal program based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* ("Uniform Guidance"). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about LIFQHC's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the major federal program. However, our audit does not provide a legal determination of LIFQHC's compliance.

Opinion on the Major Federal Program

In our opinion, LIFQHC complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended December 31, 2018.

Report on Internal Control Over Compliance

Management of LIFQHC is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered LIFQHC's internal control over compliance with the types of requirements that could have a direct and material effect on its major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each of its major federal programs and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of LIFQHC's internal control over compliance.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Baker Tilly Virchaw Krause, LP

New York, New York May 22, 2019

Schedule of Findings and Questioned Costs December 31, 2018

Section I - Summary of Auditors' Results

Financial Statements

Type of auditors' report issued:	Unmodified			
 Internal control over financial reporting: Material weakness(es) identified? Significant deficiency(ies) identified? Noncompliance material to financial statemen 	yes X no yes X none reported ts noted? yes X no			
Federal Awards				
 Internal control over major federal programs: Material weakness(es) identified? Significant deficiency(ies) identified? 	yes X no yes X none reported			
Type of auditors' report issued on compliance federal programs:	for major Unmodified			
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?yesX_no				
Identification of major federal programs:				
CFDA Number(s)	Name of Federal Program or Cluster			
10.557	Special Supplemental Nutrition program for Women, Infants and Children Program			
Dollar threshold used to distinguish between Type B programs:	Гуре A and \$750,000			
Auditee qualified as low-risk auditee?	<u>X</u> yesno			

Schedule of Findings and Questioned Costs December 31, 2018

Section II - Financial Statement Findings

None.

Section III - Federal Award Findings and Questioned Costs

None.

Section IV - Summary of Prior Year Audit Findings

No prior year findings.